Biomemory
PrivateLast Round
Grant
Mar 4, 2026
Total Funding Raised
$23.2M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Biomemory operates in AI, Data & Cloud Infrastructure and is based in Paris. Its latest recorded funding round was a Grant round in March 2026.
Biomemory is a biotechnology company that develops IT-friendly DNA-based data storage and cybersecurity solutions for data center environments.
Sector
AI, Data & Cloud Infrastructure
Verticals
Data Protection, Cloud Infrastructure, Biotechnology
Business Model
B2B
Customer Profile
Hardware Sales, Services & Consulting, Government Contracts
AI Layer
Infrastructure
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Biomemory Comparables
Compare Biomemory with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Iridia, Inc. | 80% | |
| Atlas Data Storage | 80% | |
| Kern Systems | 79% |
For institutional investors. Book with your work email.
Biomemory Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Mar 4, 2026 | ||||
| Series A | Dec 10, 2024 | ||||
| Seed | Nov 28, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Biomemory Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Blast.club | Series A |
| Prunay Impact Studio | Seed |
| Paris Business Angels | Seed, Series A |
| ADNEXUS | Series A |
| Crédit Mutuel Innovation | Series A |
| Groupe Prunay | Series A |
| Next Sequence | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 5, 2026
Job posting reveals acquisition of an unnamed US-based competitor.
- Jun 5, 2026
Selected as a French Tech 2030 laureate.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- launchesOct 16, 2026
Biomemory launches DNA Shield, a managed service for sovereign data protection, and opens its Early Access Program in France and Massachusetts on Oct 15th '26.
For institutional investors. Book with your work email.
Biomemory Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Biomemory's valuation, stock price, and market status.
Is Biomemory a public or private company?
Biomemory is a private company.
What is the current stock price of Biomemory?
Biomemory is a private company, so its shares have no public market price. Caplight tracks Biomemory's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Biomemory worth (valuation)?
Valuation information for Biomemory is not publicly available.
Can I buy Biomemory stock?
Biomemory shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Biomemory's last funding round?
Biomemory's most recent funding round was Grant on March 4, 2026.
Who are the main investors in Biomemory?
Key investors in Biomemory include Crédit Mutuel Innovation, eureKARE, Bpifrance.
Will Biomemory IPO soon?
No public IPO plans have been announced for Biomemory.
How can I track Biomemory secondary market activity?
Caplight tracks bids, offers, and trades in Biomemory's shares on secondary markets.